Bristol Myers Squibb (CELG-RI) Change in Cash (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Change in Cash of -$635.0 million for Q1 2026, down 220.27% year-over-year from $528.0 million in Q1 2025, and up 88.47% quarter-over-quarter from -$5.5 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Change in Cash (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Change in Cash data on file, last reported at -$635.0 million in Q1 2026.
- Change in Cash for Q1 2026 came in at -$635.0 million, down 220.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 183.84% YoY), and the FY2025 annual result was -$129.0 million, up 88.99% from the prior year.
- Change in Cash advanced to -$635.0 million in Q1 2026 per CELG-RI's latest filing, from -$5.5 billion in the prior quarter.
- Over five years, Change in Cash peaked at $4.0 billion in Q4 2023 and troughed at -$5.5 billion in Q4 2025.
- A 5-year average of -$278.4 million and a median of -$623.0 million in 2023 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2022 and 2024: Change in Cash sank 2230.26% in 2022, then surged 286.35% in 2024.
- A 5-year view of Change in Cash shows it stood at $1.4 billion in 2022, then jumped by 188.82% to $4.0 billion in 2023, then tumbled by 37.89% to $2.5 billion in 2024, then tumbled by 324.45% to -$5.5 billion in 2025, then surged by 88.47% to -$635.0 million in 2026.
- Business Quant data shows CELG-RI's Change in Cash at -$635.0 million in Q1 2026, -$5.5 billion in Q4 2025, and $3.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -71.45 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -635.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -635.00 Mn |
| Dec 31, 2025 | -5.51 Bn |
| Sep 30, 2025 | 3.12 Bn |
| Jun 30, 2025 | 1.74 Bn |
| Mar 31, 2025 | 528.00 Mn |
| Dec 31, 2024 | 2.45 Bn |
| Sep 30, 2024 | 1.60 Bn |
| Jun 30, 2024 | -3.04 Bn |
| Mar 31, 2024 | -2.19 Bn |
| Dec 31, 2023 | 3.95 Bn |
| Sep 30, 2023 | -857.00 Mn |
| Jun 30, 2023 | -623.00 Mn |
| Mar 31, 2023 | -277.00 Mn |
| Dec 31, 2022 | 1.37 Bn |
| Sep 30, 2022 | -3.00 Bn |
| Jun 30, 2022 | -1.62 Bn |
| Mar 31, 2022 | -1.74 Bn |
| Dec 31, 2021 | 437.00 Mn |
| Sep 30, 2021 | 2.48 Bn |
| Jun 30, 2021 | 76.00 Mn |